Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTS NASDAQ:PMN NASDAQ:QNCX NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTSALT5 Sigma$3.90+6.0%$6.14$1.55▼$10.95$84.28M1.9114.16 million shs17.79 million shsPMNPromis Neurosciences$0.44-3.4%$0.59$0.38▼$1.59$22.87M-0.053.16 million shs436,539 shsQNCXQuince Therapeutics$1.60-0.6%$1.67$0.69▼$2.45$85.94M0.99144,235 shs349,610 shsSTTKShattuck Labs$2.28+2.2%$1.13$0.69▼$3.95$109.22M1.641.50 million shs375,000 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTSALT5 Sigma0.00%-6.70%-29.22%-58.82%+87.50%PMNPromis Neurosciences0.00%+0.36%-19.58%-10.63%-64.40%QNCXQuince Therapeutics0.00%0.00%-0.62%+23.08%+117.69%STTKShattuck Labs0.00%+18.75%+154.83%+138.27%-37.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTSALT5 Sigma$3.90+6.0%$6.14$1.55▼$10.95$84.28M1.9114.16 million shs17.79 million shsPMNPromis Neurosciences$0.44-3.4%$0.59$0.38▼$1.59$22.87M-0.053.16 million shs436,539 shsQNCXQuince Therapeutics$1.60-0.6%$1.67$0.69▼$2.45$85.94M0.99144,235 shs349,610 shsSTTKShattuck Labs$2.28+2.2%$1.13$0.69▼$3.95$109.22M1.641.50 million shs375,000 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTSALT5 Sigma0.00%-6.70%-29.22%-58.82%+87.50%PMNPromis Neurosciences0.00%+0.36%-19.58%-10.63%-64.40%QNCXQuince Therapeutics0.00%0.00%-0.62%+23.08%+117.69%STTKShattuck Labs0.00%+18.75%+154.83%+138.27%-37.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTSALT5 Sigma 0.00N/AN/AN/APMNPromis Neurosciences 3.00Buy$4.33881.50% UpsideQNCXQuince Therapeutics 3.18Buy$8.14408.93% UpsideSTTKShattuck Labs 2.86Moderate Buy$4.0075.44% UpsideCurrent Analyst Ratings BreakdownLatest PMN, QNCX, STTK, and ALTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025STTKShattuck LabsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$4.008/26/2025QNCXQuince TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/14/2025STTKShattuck LabsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$4.00 ➝ $2.008/14/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/12/2025QNCXQuince TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$9.00 ➝ $8.008/5/2025QNCXQuince TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform8/5/2025QNCXQuince TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.008/5/2025QNCXQuince TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$9.007/21/2025PMNPromis NeurosciencesLeede FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy7/17/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTSALT5 Sigma$12.53M6.73N/AN/A$0.49 per share7.96PMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/AQNCXQuince TherapeuticsN/AN/AN/AN/A$0.69 per shareN/ASTTKShattuck Labs$5.72M19.09N/AN/A$1.67 per share1.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTSALT5 Sigma-$6.24MN/A0.00∞N/A-74.89%-179.27%-16.28%N/APMNPromis Neurosciences$2.78M-$0.21N/AN/AN/AN/A-266.69%-131.59%11/13/2025 (Estimated)QNCXQuince Therapeutics-$56.83M-$1.09N/AN/AN/AN/A-187.49%-42.47%11/12/2025 (Estimated)STTKShattuck Labs-$75.41M-$1.21N/AN/AN/AN/A-81.80%-71.46%11/13/2025 (Estimated)Latest PMN, QNCX, STTK, and ALTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025STTKShattuck Labs-$0.25-$0.24+$0.01-$0.24N/AN/A8/13/2025Q2 2025PMNPromis Neurosciences-$0.22-$0.29-$0.07-$0.29N/AN/A8/11/2025Q2 2025QNCXQuince Therapeutics-$0.28-$0.34-$0.06-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTSALT5 SigmaN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTSALT5 Sigma1.450.880.88PMNPromis NeurosciencesN/A0.970.97QNCXQuince Therapeutics1.455.005.00STTKShattuck LabsN/A10.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTSALT5 Sigma6.27%PMNPromis Neurosciences50.13%QNCXQuince Therapeutics30.75%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipALTSALT5 Sigma4.90%PMNPromis Neurosciences6.11%QNCXQuince Therapeutics20.30%STTKShattuck Labs12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTSALT5 Sigma17021.61 million20.55 millionN/APMNPromis Neurosciences551.81 million48.64 millionNot OptionableQNCXQuince Therapeutics6053.71 million42.81 millionOptionableSTTKShattuck Labs10047.90 million42.16 millionOptionablePMN, QNCX, STTK, and ALTS HeadlinesRecent News About These CompaniesShattuck Labs files to sell 105.27M shares of common stock for holdersSeptember 19 at 10:58 PM | msn.comShould You Buy Shattuck Labs, Inc. (STTK) After Golden Cross?September 19 at 10:55 AM | zacks.comShattuck Labs, Inc. (NASDAQ:STTK) Short Interest Down 25.1% in AugustSeptember 18 at 2:53 PM | marketbeat.comShattuck Labs Inc : STTKSeptember 17, 2025 | 247wallst.comShattuck Labs (NASDAQ:STTK) Rating Increased to Hold at Wall Street ZenSeptember 15, 2025 | marketbeat.comShattuck Labs (NASDAQ:STTK) Upgraded at Wall Street ZenSeptember 14, 2025 | americanbankingnews.comShattuck Labs, Inc. (NASDAQ:STTK) Receives $4.00 Average Price Target from BrokeragesSeptember 13, 2025 | americanbankingnews.comQ3 Earnings Forecast for Shattuck Labs Issued By WedbushSeptember 12, 2025 | marketbeat.comQ3 Earnings Estimate for Shattuck Labs Issued By WedbushSeptember 11, 2025 | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at WedbushSeptember 10, 2025 | marketbeat.comShattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by AnalystsSeptember 10, 2025 | marketbeat.comWedbush Initiates Coverage on Shattuck Labs (NASDAQ:STTK)September 10, 2025 | americanbankingnews.comWedbush Initiates Coverage of Shattuck Labs (STTK) with Outperform RecommendationSeptember 9, 2025 | msn.comShattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?September 8, 2025 | zacks.comWall Street Zen Upgrades Shattuck Labs (NASDAQ:STTK) to "Hold"September 8, 2025 | marketbeat.comShattuck Labs (NASDAQ:STTK) Director Mona Ashiya Buys 6,306,127 SharesSeptember 3, 2025 | insidertrades.comOrbiMed Advisors buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3, 2025 | investing.comAshiya Mona buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3, 2025 | investing.comShattuck Labs Closes $103M Private Placement DealAugust 26, 2025 | msn.comShattuck Labs Secures $103 Million in Private Placement to Advance SL-325 for Autoimmune Diseases and Appoints New Board MembersAugust 26, 2025 | quiverquant.comQShattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of DirectorsAugust 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMN, QNCX, STTK, and ALTS Company DescriptionsALT5 Sigma NASDAQ:ALTS$3.90 +0.22 (+5.98%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$3.94 +0.04 (+0.90%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Promis Neurosciences NASDAQ:PMN$0.44 -0.02 (-3.39%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.45 +0.00 (+1.02%) As of 09/19/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Quince Therapeutics NASDAQ:QNCX$1.60 -0.01 (-0.62%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 09/19/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Shattuck Labs NASDAQ:STTK$2.28 +0.05 (+2.24%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$2.30 +0.02 (+0.66%) As of 09/19/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
